Seres Therapeutics, Inc. Share-based Payment Arrangement, Expense
Seres Therapeutics, Inc. (MCRB) reported Share-based Payment Arrangement, Expense of $1.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-05
- Seres Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $1.74M, a 25.68% decline year-over-year.
- Seres Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.77M, a 37.35% decline year-over-year.
- Seres Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $3.20M, a 15.03% decline year-over-year.
- Seres Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $2.48M, a 52.11% decline year-over-year.
- Seres Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $10.84M, a 48.31% decline from fiscal 2024.
- Seres Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $20.97M, a 38.50% decline from fiscal 2023.
- Seres Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $34.10M, a 33.82% increase from fiscal 2022.
- Seres Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $25.48M, a 26.01% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.74M 10-Q · filed 2026-08-05 | $3.50M 10-Q · filed 2026-08-05 | $6.70M derived: sum of 3 quarters · filed 2026-08-05 | $9.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.77M 10-Q · filed 2026-05-05 | $4.96M derived: sum of 2 quarters · filed 2026-05-05 | $7.45M derived: sum of 3 quarters · filed 2026-05-05 | $9.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.68M derived: sum of 2 quarters · filed 2026-03-12 | $8.02M derived: sum of 3 quarters · filed 2026-08-05 | $10.84M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.48M 10-Q · filed 2025-11-05 | $4.82M derived: sum of 2 quarters · filed 2026-08-05 | $7.64M 10-Q · filed 2025-11-05 | $11.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.34M 10-Q · filed 2026-08-05 | $5.16M 10-Q · filed 2026-08-05 | $8.92M derived: sum of 3 quarters · filed 2026-08-05 | $14.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.82M 10-Q · filed 2026-05-05 | $6.58M derived: sum of 2 quarters · filed 2026-05-05 | $11.77M derived: sum of 3 quarters · filed 2026-05-05 | $17.30M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $8.95M derived: sum of 2 quarters · filed 2026-03-12 | $14.48M derived: sum of 3 quarters · filed 2026-03-12 | $20.97M 10-K · filed 2026-03-12 |
| 2024-09-30 | $5.18M 10-Q · filed 2025-11-05 | $10.72M derived: sum of 2 quarters · filed 2025-11-05 | $17.21M 10-Q · filed 2025-11-05 | $22.29M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $5.53M 10-Q · filed 2025-08-06 | $12.02M 10-Q · filed 2025-08-06 | $17.11M derived: sum of 3 quarters · filed 2026-03-12 | $25.78M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $6.49M 10-Q · filed 2025-05-07 | $11.57M derived: sum of 2 quarters · filed 2026-03-12 | $20.25M derived: sum of 3 quarters · filed 2026-03-12 | $33.74M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $13.76M derived: sum of 2 quarters · filed 2026-03-12 | $27.25M derived: sum of 3 quarters · filed 2026-03-12 | $34.10M 10-K · filed 2026-03-12 |
| 2023-09-30 | $8.67M 10-Q · filed 2024-11-13 | $22.16M derived: sum of 2 quarters · filed 2024-11-13 | $29.02M 10-Q · filed 2024-11-13 | $36.31M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $13.49M 10-Q · filed 2024-08-13 | $20.34M 10-Q · filed 2024-08-13 | $27.63M derived: sum of 3 quarters · filed 2025-03-13 | $34.00M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $6.85M 10-Q · filed 2024-05-08 | $14.14M derived: sum of 2 quarters · filed 2025-03-13 | $20.50M derived: sum of 3 quarters · filed 2025-03-13 | $27.25M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $7.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $13.65M derived: sum of 2 quarters · filed 2025-03-13 | $20.40M derived: sum of 3 quarters · filed 2025-03-13 | $25.48M 10-K · filed 2025-03-13 |
| 2022-09-30 | $6.36M 10-Q · filed 2023-11-02 | $13.11M derived: sum of 2 quarters · filed 2023-11-02 | $18.19M 10-Q · filed 2023-11-02 | $23.86M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $6.75M 10-Q · filed 2023-08-08 | $11.83M 10-Q · filed 2023-08-08 | $17.50M derived: sum of 3 quarters · filed 2024-03-05 | $23.35M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $5.08M 10-Q · filed 2023-05-09 | $10.75M derived: sum of 2 quarters · filed 2024-03-05 | $16.60M derived: sum of 3 quarters · filed 2024-03-05 | $21.68M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $11.52M derived: sum of 2 quarters · filed 2024-03-05 | $16.60M derived: sum of 3 quarters · filed 2024-03-05 | $20.22M 10-K · filed 2024-03-05 |
| 2021-09-30 | $5.85M 10-Q · filed 2022-11-02 | $10.92M derived: sum of 2 quarters · filed 2022-11-02 | $14.55M 10-Q · filed 2022-11-02 | $17.25M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $5.08M 10-Q · filed 2022-08-03 | $8.70M 10-Q · filed 2022-08-03 | $11.40M derived: sum of 3 quarters · filed 2023-03-07 | $13.65M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $3.62M 10-Q · filed 2022-05-04 | $6.33M derived: sum of 2 quarters · filed 2023-03-07 | $8.57M derived: sum of 3 quarters · filed 2023-03-07 | $10.49M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $4.95M derived: sum of 2 quarters · filed 2023-03-07 | $6.87M derived: sum of 3 quarters · filed 2023-03-07 | $8.82M 10-K · filed 2023-03-07 |
| 2020-09-30 | $2.25M 10-Q · filed 2021-11-10 | $4.16M derived: sum of 2 quarters · filed 2021-11-10 | $6.12M 10-Q · filed 2021-11-10 | $8.27M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $1.91M 10-Q · filed 2021-08-03 | $3.87M 10-Q · filed 2021-08-03 | $6.02M derived: sum of 3 quarters · filed 2022-03-01 | $8.05M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $1.96M 10-Q · filed 2021-05-04 | $4.10M derived: sum of 2 quarters · filed 2022-03-01 | $6.14M derived: sum of 3 quarters · filed 2022-03-01 | $8.24M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.18M derived: sum of 2 quarters · filed 2022-03-01 | $6.28M derived: sum of 3 quarters · filed 2022-03-01 | $8.34M 10-K · filed 2022-03-01 |
| 2019-09-30 | $2.04M 10-Q · filed 2020-11-09 | $4.13M derived: sum of 2 quarters · filed 2020-11-09 | $6.20M 10-Q · filed 2020-11-09 | $9.95M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-06-30 | $2.10M 10-Q · filed 2020-07-28 | $4.16M 10-Q · filed 2020-07-28 | $7.92M derived: sum of 3 quarters · filed 2021-03-02 | $12.23M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-03-31 | $2.06M 10-Q · filed 2020-05-07 | $5.82M derived: sum of 2 quarters · filed 2021-03-02 | $10.14M derived: sum of 3 quarters · filed 2021-03-02 | $14.47M derived: sum of 4 quarters · filed 2021-03-02 |
| 2018-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $8.07M derived: sum of 2 quarters · filed 2021-03-02 | $12.40M derived: sum of 3 quarters · filed 2021-03-02 | $16.64M 10-K · filed 2021-03-02 |
| 2018-09-30 | $4.32M 10-Q · filed 2019-11-05 | $8.65M derived: sum of 2 quarters · filed 2019-11-05 | $12.89M 10-Q · filed 2019-11-05 | $17.10M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $4.33M 10-Q · filed 2019-08-06 | $8.57M 10-Q · filed 2019-08-06 | $12.78M derived: sum of 3 quarters · filed 2020-03-02 | $17.15M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $4.24M 10-Q · filed 2019-05-02 | $8.45M derived: sum of 2 quarters · filed 2020-03-02 | $12.82M derived: sum of 3 quarters · filed 2020-03-02 | $17.32M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $8.58M derived: sum of 2 quarters · filed 2020-03-02 | $13.08M derived: sum of 3 quarters · filed 2020-03-02 | $17.36M 10-K · filed 2020-03-02 |
| 2017-09-30 | $4.37M 10-Q · filed 2018-11-08 | $8.87M derived: sum of 2 quarters · filed 2018-11-08 | $13.15M 10-Q · filed 2018-11-08 | $17.14M derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-06-30 | $4.50M 10-Q · filed 2018-08-02 | $8.78M 10-Q · filed 2018-08-02 | $12.77M derived: sum of 3 quarters · filed 2019-03-06 | $17.02M derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-03-31 | $4.28M 10-Q · filed 2018-05-09 | $8.27M derived: sum of 2 quarters · filed 2019-03-06 | $12.52M derived: sum of 3 quarters · filed 2019-03-06 | $17.23M derived: sum of 4 quarters · filed 2019-03-06 |
| 2016-12-31 | $3.99M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $8.24M derived: sum of 2 quarters · filed 2019-03-06 | $12.95M derived: sum of 3 quarters · filed 2019-03-06 | $16.86M 10-K · filed 2019-03-06 |
| 2016-09-30 | $4.24M 10-Q · filed 2017-11-08 | $8.96M derived: sum of 2 quarters · filed 2017-11-08 | $12.87M 10-Q · filed 2017-11-08 | $15.65M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $4.72M 10-Q · filed 2017-08-03 | $8.62M 10-Q · filed 2017-08-03 | $11.41M derived: sum of 3 quarters · filed 2018-03-08 | $13.91M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $3.90M 10-Q · filed 2017-05-04 | $6.69M derived: sum of 2 quarters · filed 2018-03-08 | $9.20M derived: sum of 3 quarters · filed 2018-03-08 | $12.27M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $5.29M derived: sum of 2 quarters · filed 2018-03-08 | $8.37M derived: sum of 3 quarters · filed 2018-03-08 | $9.69M 10-K · filed 2018-03-08 |
| 2015-09-30 | $2.51M 10-Q · filed 2016-11-10 | $5.58M derived: sum of 2 quarters · filed 2016-11-10 | $6.91M 10-Q · filed 2016-11-10 | $8.28M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $3.07M 10-Q · filed 2016-08-11 | $4.40M 10-Q · filed 2016-08-11 | $5.77M derived: sum of 3 quarters · filed 2017-03-16 | $6.37M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $1.33M 10-Q · filed 2016-05-16 | $2.69M derived: sum of 2 quarters · filed 2017-03-16 | $3.30M derived: sum of 3 quarters · filed 2017-03-16 | $3.35M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $1.97M derived: sum of 2 quarters · filed 2017-03-16 | $2.02M derived: sum of 3 quarters · filed 2017-03-16 | $2.07M 10-K · filed 2017-03-16 |
| 2014-09-30 | $603.00K 10-Q · filed 2015-11-12 | $655.00K derived: sum of 2 quarters · filed 2015-11-12 | $700.00K 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $52.00K 10-Q · filed 2015-08-10 | $97.00K 10-Q · filed 2015-08-10 | ||
| 2013-12-31 | $209.00K 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |